Codexis, Inc.
Develops protein-based biocatalysts that enable pharmaceutical, biotechnology, and fine chemical companies to develop products quicker and more economically
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Codexis stock, believing it could rise significantly in value.
Financial Health
Codexis is performing well with strong revenue and cash flow, showing good profit potential.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring CDXS
Synthetic-Bio Foundries
Discover companies that are programming living cells to create the materials of tomorrow. These carefully selected stocks represent pioneers in replacing petrochemical processes with cleaner, more efficient biological alternatives - essentially turning microbes into tiny manufacturing plants.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Platform-driven Growth
CodeEvolver® aims to accelerate enzyme discovery, supporting collaborations and licences that can drive revenue — though commercial uptake can take time.
Partner-led Commercial Model
Codexis often monetises through partnerships and royalties with large pharma and industrial customers, which can provide scalable opportunities but also concentration risk.
Small-cap Volatility Risk
Market moves can be pronounced for small biotechnology firms; investors should consider suitability and diversification before taking a position.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals develops treatments for diseases including cystic fibrosis and cancer.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a leading biotechnology company that develops and manufactures innovative medicines for serious medical conditions.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics based on RNA interference (RNAi).
